La Jolla Institute for Allergy and Immunology

Kirin Beer Kabushiki Kaisha

Kyowa Hakko Kirin Co., Limited

Gemini Science, Inc.

Toshifumi Mikayama

Nobuaki Takahashi

Kimishige Ishizaka

Xingjie Chen

Hitoshi Yoshida

Walker R Force

Shinichiro Kato

Yoichi Kato

Rongfang Wang

Stephen P Schoenberger

Nobuaki Takahasi

Yun-Cai Liu

Tatsumi Nakano

Ryota Kuroki

Hiroshi Watarai

Takafumi Tomura

Nobuaki Takashi

Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Human monoclonal antibodies to influenza M2 protein and methods of making and using same

An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

Anti-CD40 monoclonal antibody

The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.

Human anti-CD40 antibodies

This invention provides pharmaceutical compositions and methods for controlling and modifying Natural Killer (NK) cell and T cell functions by manipulation of 'mast cell function-associated antigen,' or 'MAFA,' polypeptide-mediated cell signaling. The invention provides a pharmaceutical compositions and methods using an agent that specifically binds to an MAFA ligand on a target cell and prevents or inhibits NK- or T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell. Preventing or inhibiting an NK- or a T cell-expressed cell surface MAFA from binding to the MAFA ligand on the target cell prevents or inhibits the cell surface MAFA from generating an inhibitory signal to the NK or the T cell. The invention also provides pharmaceutical compositions and methods using an agent that specifically binds to an NK- or a T cell-expressed cell surface MAFA and prevents or inhibits the NK- or T cell-expressed cell surface MAFA from binding to a MAFA ligand or generating an inhibitory signal to the NK or the T cell. The invention also provides pharmaceutical compositions and methods using an agent that specifically binds to an NK- or a T cell-expressed cell surface MAFA and inhibits an NK cell or T cell activity.

Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them

Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for recombinant production of biologically active polypeptides from a structural gene encoding the polypeptide.

Method for recombinant production of biologically active polypeptides

Antigen non-specific human glycosylation inhibiting factor derivatives having the inmunosuppressive activity in which a mutation was introduced for replacement, deletion and/or insertion of a part of the amino acid sequence of SEQ ID NO:21, and/or which has received a chemical modification of one or more amino acid residue(s) in the amino acid sequence of SEQ ID NO:21, wherein the mutation and the chemical modification attenuate the strength of an intermolecular association in the region, which participates in trimerization, of an antigen non-specific human glycosylation inhibiting factor having the amino acid sequence of SEQ ID NO:21; DNAs containing a base sequence encoding the amino acid sequence of the antigen non-specific human glycosylation inhibiting factor derivative; recombinant vectors containing the DNAs; prokaryotic or eukaryotic cells transformed with the DNAs; methods of producing the antigen non-specific human glycosylation inhibiting factor derivatives; pharmaceutical compositions comprising the antigen non-specific human glycosylation inhibiting factor derivative and a pharmaceutically acceptable carrier; and methods of suppressing a human immune response to an antigen are provided.

Antigen non-specific glycosylation inhibiting factor derivatives

Method for recombinant production of antigen non-specific glycosylation

Growing community of inventors

Takasaki, Japan

Toshifumi Mikayama